European Week Against Cancer 2022 – Interview with Santiago Aguirre, Market Lead Europe Oncology, Sanofi


Big Changes Start Small


Opinion: A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare


EuropaBio NAC Summit 2022: key recommendations on how National associations can deliver Europe’s innovation, investment and excellence in biotechnology


EuropaBio Statement on Rare Disease Day


EuropaBio becomes a partner of a new European partnership for health


EuropaBio: Revision of the EU general pharmaceuticals legislation for a healthier tomorrow


Interview with Ingmar Hoerr, CureVac Founder and holder of the first patents associated with mRNA

EuropaBio sat down with New Member Olon, to find out about their Plans to Expand their Biotechnology Platform.

The review of the general pharmaceutical legislation: an opportunity that should not be missed?


Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem


EuropaBio Patient Bio-Forum: challenges and future potential of European Reference Networks


Artificial intelligence: investing in new technologies in healthcare

What if machine learning and artificial intelligence could learn to detect one of the most common forms of blood cancer, through evaluating data based on the gene activity of blood cells?

Treatment Without Borders: The EU Case for Equitable Patient Access to Advanced Therapies


EuropaBio response to the European Commission Public Consultation on the Regulations for Orphan Medicinal Products and Paediatrics

EuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.

EuropaBio response to the Public Consultation ‘Digital Health Data and Services – The European Health Data Space’


EuropaBio response to the European Commission Public Consultation on the Regulation for Orphan Medicinal Products and Paediatrics: the value brought by the technology to patients and society should be well recognised


EuropaBio’s response to the EC consultation on patients’ rights in cross-border healthcare


A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders to ensure that COVID vaccines and treatments get to the patients in the world who most need them.

EPSCO Council conclusions: EuropaBio calls for more pragmatic approach addressing access, availability and affordability of medicines


EuropaBio invited healthcare biotech SMEs to learn about EU Policy Priorities

Become a member